Morning Briefing
Summaries of health policy coverage from major news organizations
National Study Underscores Disparities In State-Level HPV Vaccine Uptake
CIDRAP: Study Highlights State-Level Differences In HPV Vaccine Uptake
A new study shows wide state-level variation in the uptake of the human papillomavirus (HPV) vaccine. The study, which analyzed data from the 2023 National Immunization Survey-Teen (NIS-Teen), found that states in the Northeast census region had significantly higher odds of HPV vaccine uptake, while states in the South had significantly lower odds. But even within regions, there was wide variability. (Dall, 5/13)
MedPage Today: Personalized DNA Vaccine Shows Promise In Brain Cancer
An adjuvant personalized DNA vaccine was safe and demonstrated promising efficacy among patients with MGMT-unmethylated glioblastoma in a phase I trial. The vaccine caused no serious adverse events and extended overall survival in the nine patients included in the study compared with historical outcomes, reported Tanner M. Johanns, MD, PhD, of Washington University School of Medicine in St. Louis, and colleagues in Nature Cancer. (Bassett, 5/13)
CIDRAP: Review By Vaccine Integrity Project Supports Tdap Vaccination During Pregnancy
Infants born to mothers who received the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy are less likely to contract pertussis (whooping cough), develop complications, and die of the disease than those without such protection, a report today from the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) suggests. (Van Beusekom, 5/13)
Bloomberg: Hantavirus Vaccine Research Stalls In Chile After Funding Runs Out
Virologist María Inés Barría remembers the Eureka moment from a decade ago. Barría and her team in Chile had been working for months on antibodies to treat hantavirus that kills about one-in-three people who contract it. The breakthrough came around 2016, when a telltale fluorescent green glow indicating the presence of the virus disappeared under a microscope. ... After later success in animal trials, the lab was ready to work with international partners to start testing on humans. Then they ran out of money. (Mufarech and Smith, 5/13)
Also —
MedPage Today: Next-Gen BCL2 Inhibitor Approved For Aggressive Lymphoma
The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma. A next-generation product in the drug class, sonrotoclax is indicated for adults previously treated with two or more lines of therapy that includes a Bruton's tyrosine kinase (BTK) inhibitor. (Bassett, 5/13)
